In Reply.—We thank Özsoylu for his comments. The purpose of our letter was not to discuss the different aspects of leishmaniasis in full but to bring the possible loopholes in its diagnosis to the attention of those who are less familiar with this disease but who will probably be increasingly confronted with it. The references that we selected were mainly intended to illustrate the danger of unrecognized leishmaniasis. For the same reason we did not discuss in detail the therapeutic aspects.
When treating our patient we followed the recommendations of Brysecon,1 which were based on a large survey of the literature. Even with splenomegaly persisting for some time, treatment in our patient can be considered successful since no relapses have occurred after more than 20 months. Judging from his results, Özsoylu's treatment regimen is an obvious alternative. It appears that both treatment with lower doses of pentavalent antimony for a
MAHIEU LM, VAN ACKER KJ. Treatment of Visceral Leishmaniasis-Reply. Am J Dis Child. 1992;146(9):1021. doi:10.1001/archpedi.1992.02160210023011